Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in children

• Main Authors: Y. V. Skvortsova, D. N. Balashov, V. M. Delyagin
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2016-12-01
• Series: Медицинский совет
• Subjects: трансплантация гемопоэтических стволовых клеток; реакция трансплантат против хозяина; патогенез; клиника; лечение; transplantation of hematopoietic stem cells; reaction; graft-versus-host disease; pathogenesis; clinical pattern; treatment
• Online Access: https://www.med-sovet.pro/jour/article/view/23
• ISSN: 2079-701X; 2658-5790

Up to 60 thousand hematopoietic stem cell transplantations (HSCT) are carried out globally all over the world. The outcome of HSCT is largely determined by the probability and severity of the graft-versus-host reaction/disease (GVHD). Treatment involves corticosteroids. Antithymocyte globulin, extracorporeal photopheresis, monoclonal antibodies to interleukins or their receptors, methotrexate, cyclosporine, tacrolimus, sirolimus, antithymocyte globulin, etc. are used in steroid-refractory GVHD. It is worth to mention that mycophenolate mofetil, esther of mycophenolic acid, blocks proliferation of T and B lymphocytes. In patients who are refractory to corticosteroids, the use of mycophenolate mofetil in isolation or in combination with cyclosporine, tacrolimus seems to be justified.